Key terms
About BIO
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BIO news
Nov 01
5:12am ET
Wells Fargo Remains a Hold on Bio-Rad Laboratories (BIO)
Oct 31
8:58am ET
Bio-Rad price target raised to $469 from $446 at RBC Capital
Oct 31
6:56am ET
Bio-Rad price target raised to $450 from $400 at Citi
Oct 31
6:50am ET
RBC Capital Sticks to Their Buy Rating for Bio-Rad Laboratories (BIO)
Oct 31
12:08am ET
Bio-Rad Laboratories Reports Q3 2024 Earnings Growth
Oct 30
4:27pm ET
Bio-Rad reports Q3 EPS $2.01, consensus $1.16
Oct 30
4:26pm ET
Bio-Rad sees non-GAAP revenue down 2.5%-4% for FY24
Oct 24
9:58pm ET
Bio-Rad Laboratories (BIO) Gets a Buy from RBC Capital
Oct 08
5:02am ET
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Argenica Therapeutics Ltd (AU:AGN) and Bio-Rad Laboratories (BIO)
Oct 01
6:00am ET
Bio-Rad upgraded to Buy from Neutral at Citi
Sep 10
2:15pm ET
Bio-Rad COO Last sells $990K in company shares
Sep 06
5:40pm ET
S&P announces changes to S&P 400, 600 indexes for quarterly rebalance
Sep 06
5:25pm ET
Palantir, Dell Technologies, Erie Indemnity to be added to S&P 500 on 9/23
Aug 28
6:22am ET
Wells Fargo initiates Bio-Rad with an Equal Weight, $340 price target
Aug 27
4:21pm ET
Bio-Rad initiated with an Equal Weight at Wells Fargo
Aug 20
8:58am ET
Bio-Rad Laboratories Welcomes New President and COO
Aug 20
8:40am ET
Bio-Rad Labcorp announces Jon DiVincenzo as COO
Aug 16
6:45am ET
Bio-Rad Laboratories (BIO) Receives a Buy from RBC Capital
Aug 08
4:58pm ET
OncoCyte announces successful GraftAssure beta launch
Nov 04
9:15am ET
Interpreting Bio-Rad (BIO) International Revenue Trends
Oct 31
8:42am ET
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
Oct 30
5:50pm ET
Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates
Oct 29
11:26am ET
What to Expect From These 3 MedTech Stocks This Earnings Season
Oct 23
10:02am ET
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Oct 23
5:00am ET
FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?
BIO Financials
Key terms
Ad Feedback
BIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
